nanatinostat

Nanatinostat is an orally bioavailable, second-generation hydroxamic acid-based small molecule inhibitor of histone deacetylase (HDAC), with selectivity for class I HDACs (particularly HDAC 1 to 3)[3][4][5]. By inhibiting HDACs, nanatinostat leads to the accumulation of highly acetylated histones, chromatin remodeling, and selective transcriptional activation of tumor suppressor genes. This results in inhibition of tumor cell division and induction of apoptosis[1][3]. Nanatinostat is being developed primarily for Epstein-Barr virus (EBV)-associated cancers—including EBV-positive lymphomas, nasopharyngeal carcinoma, EBV-related gastric carcinoma, leiomyosarcoma, and other EBV-associated malignancies—often in combination with valganciclovir[4][5]. The drug has shown encouraging efficacy in relapsed/refractory lymphoma patients and is currently under investigation in phase II clinical trials[4][7]. It was originally developed by Chroma Therapeutics and further developed by Viracta Therapeutics[7].

Other names

Hdac inhibitor CHR-3996Nanatinostat [USAN]Tractinostat